Herbert Virgin - 25 Jan 2022 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
EVP, Research & CSO
Signature
/s/ Howard Horn, Attorney-in-Fact
Issuer symbol
VIR
Transactions as of
25 Jan 2022
Transactions value $
-$42,529
Form type
4
Filing time
26 Jan 2022, 18:35:06 UTC
Previous filing
13 Jan 2022
Next filing
09 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Options Exercise $2,103 +1,375 +1.3% $1.53* 109,075 25 Jan 2022 Direct
transaction VIR Common Stock Sale -$44,632 -1,375 -1.3% $32.46 107,700 25 Jan 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Options Exercise $0 -1,375 -0.61% $0 222,255 25 Jan 2022 Common Stock 1,375 $1.53 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021.
F2 The option is fully vested and exercisable.